Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes
Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s share data. Mereo BioPharma